NU SKIN ENTERPRISES, INC. NUS
Nu Skin Enterprises, Inc. develops and distributes a comprehensive line of premium-quality beauty and wellness solutions in nearly 50 markets worldwide. In 2025, our revenue of
$1.5 billion was primarily generated by our two primary product categories: beauty products and wellness products. We operate in the direct selling channel, primarily utilizing person-to-person
marketing to promote and sell our products, including through the use of social and digital platforms.
synergistic and adjacent growth through our strategic investment arm known as Rhyz Inc., which we formed in 2018. Our Rhyz businesses primarily consist of consumer, technology and manufacturing companies. In 2025, the Rhyz companies generated
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.49B | $1.73B | $1.97B | $2.23B | $2.70B | $2.58B | $2.42B | $2.68B | $2.28B | $2.21B |
| Cost of revenue | $453.8M | $550.2M | $611.9M | $630.9M | $675.2M | $658.0M | $581.4M | $634.1M | $502.1M | $500.5M |
| Gross profit | $1.03B | $1.18B | $1.36B | $1.59B | $2.02B | $1.92B | $1.84B | $2.04B | $1.78B | $1.71B |
| R&D | $10.8M | $13.0M | $22.6M | $23.3M | $27.2M | $23.3M | $30.1M | $23.0M | $22.0M | $24.3M |
| SG&A | $432.1M | $479.0M | $546.9M | $555.8M | $654.4M | $636.5M | $616.0M | $662.3M | $564.5M | $554.2M |
| Total operating expenses | $965.6M | $1.33B | $1.31B | $1.48B | $1.79B | $1.67B | $1.57B | $1.80B | $1.50B | $1.48B |
| Operating income | $65.8M | -$151.6M | $48.3M | $110.8M | $234.0M | $257.6M | $267.4M | $240.9M | $274.5M | $231.1M |
| Interest expense | $13.9M | $26.4M | $25.6M | $13.5M | $11.0M | $13.1M | $19.2M | $21.8M | $22.2M | $15.6M |
| Pre-tax income | $196.2M | -$175.1M | $26.6M | $89.0M | $232.5M | $256.2M | $255.2M | $219.7M | $265.6M | $212.8M |
| Income tax | $36.0M | $28.5M | $18.0M | $15.8M | $85.2M | $64.9M | $81.6M | $97.8M | $136.1M | $69.8M |
| Net income | $160.2M | -$146.6M | $8.6M | $104.8M | $147.3M | $191.4M | $173.6M | $121.9M | $129.4M | $143.1M |
| EPS, basic | 3.25 | -2.95 | 0.17 | 2.10 | 2.93 | 3.66 | 3.13 | 2.21 | 2.45 | 2.58 |
| EPS, diluted | 3.18 | -2.95 | 0.17 | 2.07 | 2.86 | 3.63 | 3.10 | 2.16 | 2.36 | 2.55 |
| Shares, diluted (wtd. avg.) | $50.3M | $49.7M | $49.9M | $50.5M | $51.4M | $52.8M | $55.9M | $56.5M | $54.9M | $56.1M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $238.6M | $186.9M | $256.1M | $264.7M | $339.6M | $402.7M | $335.6M | $386.9M | $426.4M | $357.2M |
| Short-term investments | $1.2M | $11.1M | $11.8M | $13.8M | $15.2M | $21.2M | $8.4M | $11.3M | $11.8M | $10.9M |
| Receivables | $39.5M | $50.8M | $58.7M | $47.4M | $41.3M | $63.4M | $50.4M | — | — | — |
| Inventory | $178.6M | $190.2M | $280.0M | $346.2M | $399.9M | $314.4M | $275.9M | $295.8M | $253.5M | $249.9M |
| Total current assets | $547.7M | $538.6M | $701.9M | $759.9M | $873.0M | $903.2M | $740.2M | $799.2M | $777.8M | $714.3M |
| Property, plant and equipment | $377.2M | $379.6M | $433.0M | $444.8M | $453.7M | $468.2M | $453.6M | $464.5M | $464.6M | $444.7M |
| Goodwill | $83.6M | $83.6M | $218.2M | $206.4M | $206.4M | $203.0M | $196.6M | $196.6M | $115.0M | $115.0M |
| Other intangibles | $42.6M | $74.3M | $95.3M | $66.7M | $77.0M | $89.5M | $80.3M | $90.0M | $67.6M | $63.6M |
| Total assets | $1.41B | $1.47B | $1.81B | $1.82B | $1.91B | $1.96B | $1.77B | $1.69B | $1.59B | $1.47B |
| Accounts payable | $26.2M | $34.9M | $43.1M | $54.0M | $50.0M | $66.2M | $39.0M | $47.6M | $50.3M | $41.3M |
| Short-term debt | $20.0M | $30.0M | $25.0M | $25.0M | $107.5M | $30.0M | $27.5M | $69.5M | $77.8M | $82.7M |
| Total current liabilities | $263.7M | $296.6M | $328.9M | $359.2M | $529.7M | $542.9M | $356.8M | $439.7M | $447.4M | $399.0M |
| Long-term debt | $204.2M | $363.6M | $478.0M | $377.5M | $268.8M | $305.4M | $334.5M | $361.0M | $310.8M | $334.2M |
| Total liabilities | $600.1M | $817.5M | $986.7M | $923.7M | $993.7M | $1.06B | $893.7M | $912.6M | $885.3M | $810.0M |
| Retained earnings | $1.86B | $1.71B | $1.87B | $1.94B | $1.91B | $1.84B | $1.73B | $1.64B | $1.61B | $1.56B |
| Total equity | $805.2M | $651.5M | $822.0M | $897.3M | $912.8M | $894.3M | $875.3M | $781.9M | $704.6M | $664.1M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $80.3M | $111.7M | $118.6M | $108.1M | $141.6M | $379.1M | $177.9M | $202.7M | $302.6M | $275.3M |
| Depreciation and amortisation | $52.3M | $69.8M | $70.9M | $72.5M | $76.3M | $74.0M | $76.7M | $83.0M | $71.6M | $72.4M |
| Stock-based compensation | $24.1M | $14.8M | $15.6M | $12.4M | $23.2M | $24.1M | $9.9M | $26.6M | $19.3M | $8.9M |
| Capital expenditure | $34.3M | $41.6M | $58.5M | $59.1M | $68.6M | $63.8M | $66.1M | $70.4M | $60.2M | $50.2M |
| Investing cash flow | $170.7M | -$38.0M | -$134.5M | -$67.1M | -$88.7M | -$79.4M | -$71.4M | -$108.8M | -$92.0M | -$57.9M |
| Financing cash flow | -$202.4M | -$133.2M | $10.7M | -$99.5M | -$104.7M | -$245.2M | -$154.8M | -$116.7M | -$159.6M | -$134.7M |
| Dividends paid | $11.8M | $11.9M | $77.6M | $77.0M | $76.3M | $78.4M | $82.2M | $80.6M | $76.1M | $78.4M |
| Buybacks | $20.0M | $0 | $13.0M | $70.0M | $80.4M | $144.3M | $825.0K | $69.6M | $71.7M | $247.2M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001140361-26-005130.
Others in SIC 5122
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| MCK | MCKESSON CORP | $105.86B | 23.7x | 12.4% |
| COR | Cencora, Inc. | $63.15B | 41.6x | 9.3% |
| CAH | CARDINAL HEALTH INC | $57.49B | 34.2x | 14.2% |
| HLF | HERBALIFE LTD. | $1.30B | 5.6x | 0.9% |
| COSM | Cosmos Health Inc. | $27.5M | — | 19.9% |
| HWH | HWH International Inc. | $14.5M | — | -30.8% |
| MEDS | DataMeds AI, Inc. | $2.8M | — | 28.7% |
| HKPD | Cellyan Biotechnology Co., Ltd | — | — | — |